Team:Paris Bettencourt/Achievements
From 2012.igem.org
Line 25: | Line 25: | ||
Both part were well [[2012.igem.org/Team:Paris_Bettencourt/Semantic_containment#Results|characterized]] and works well. For the second parts, we show that as expected, one mutation is quite leaky, although it works qualitatively, but one mutation is not enough if we want to release such parts in nature. Other reasons emphasize this observation, notably the weakness of being at one mutation to recover the protein functionality. | Both part were well [[2012.igem.org/Team:Paris_Bettencourt/Semantic_containment#Results|characterized]] and works well. For the second parts, we show that as expected, one mutation is quite leaky, although it works qualitatively, but one mutation is not enough if we want to release such parts in nature. Other reasons emphasize this observation, notably the weakness of being at one mutation to recover the protein functionality. | ||
* Creation of a new category in the part registry : [http://partsregistry.org/Biosafety Semantic containment]. The aim of this category is to let people improving each part by adding for instance other amber mutations to existing part to increase the containment. | * Creation of a new category in the part registry : [http://partsregistry.org/Biosafety Semantic containment]. The aim of this category is to let people improving each part by adding for instance other amber mutations to existing part to increase the containment. | ||
- | |||
- | |||
- | |||
<div id="boston"> | <div id="boston"> | ||
'''Achievements : ''' | '''Achievements : ''' | ||
Line 35: | Line 32: | ||
** [http://partsregistry.org/Part:BBa_K914012 K914012] : pSB1A2 with one Amber Codon : Ampicillin gene resistance with 1 amber mutation | ** [http://partsregistry.org/Part:BBa_K914012 K914012] : pSB1A2 with one Amber Codon : Ampicillin gene resistance with 1 amber mutation | ||
</div> | </div> | ||
+ | </td> | ||
+ | </tr> | ||
+ | </table> | ||
+ | |||
Line 84: | Line 85: | ||
* Demonstration that all 3 generators (K914005, K914007, K914008) work and express I-SceI meganuclease in cells. [https://2012.igem.org/Team:Paris_Bettencourt/Restriction_Enzyme#Measuring_the_efficiency_of_I-SceI_.28Cloned_parts.29 [Read more]] | * Demonstration that all 3 generators (K914005, K914007, K914008) work and express I-SceI meganuclease in cells. [https://2012.igem.org/Team:Paris_Bettencourt/Restriction_Enzyme#Measuring_the_efficiency_of_I-SceI_.28Cloned_parts.29 [Read more]] | ||
- | * Characterization of 2 biobricks from TUDelft [https://2012.igem.org/Team:Paris_Bettencourt/Restriction_Enzyme# | + | <div id="boston"> |
+ | * '''[https://2012.igem.org/Team:Paris_Bettencourt/Restriction_Enzyme#New_Results [Updated for Boston] ]''' : Characterization of 2 biobricks from TUDelft [https://2012.igem.org/Team:Paris_Bettencourt/Restriction_Enzyme#Measuring_the_I-SceI_efficiency_.28TUDelft_parts.29 [Read more]]: | ||
** [http://partsregistry.org/Part:BBa_K175041 K175041]: p(LacI) controlled I-SceI homing endonuclease generator | ** [http://partsregistry.org/Part:BBa_K175041 K175041]: p(LacI) controlled I-SceI homing endonuclease generator | ||
** [http://partsregistry.org/Part:BBa_K175027 K175027]: I-SceI restriction site | ** [http://partsregistry.org/Part:BBa_K175027 K175027]: I-SceI restriction site | ||
+ | </div> | ||
* [https://2012.igem.org/Team:Paris_Bettencourt/Restriction_Enzyme#Characterization_of_pRha Characterization ] of the L-rhamnose-inducible promoter ([https://2012.igem.org/Team:Paris_Bettencourt/Restriction_Enzyme#Design pRha]). | * [https://2012.igem.org/Team:Paris_Bettencourt/Restriction_Enzyme#Characterization_of_pRha Characterization ] of the L-rhamnose-inducible promoter ([https://2012.igem.org/Team:Paris_Bettencourt/Restriction_Enzyme#Design pRha]). | ||
</tr> | </tr> | ||
Line 110: | Line 113: | ||
* [https://2012.igem.org/Team:Paris_Bettencourt/Delay#Refined_characterization_of_the_Yokobayashi_et_al._sRNA_repression_plasmidic_device Characterization] of the sRNA repression system of Yokobayashi ''et al.'' | * [https://2012.igem.org/Team:Paris_Bettencourt/Delay#Refined_characterization_of_the_Yokobayashi_et_al._sRNA_repression_plasmidic_device Characterization] of the sRNA repression system of Yokobayashi ''et al.'' | ||
* Cloning of the yiaGp stationary phase promoter | * Cloning of the yiaGp stationary phase promoter | ||
- | |||
- | |||
- | |||
<div id="boston"> | <div id="boston"> | ||
'''Achievements :''' | '''Achievements :''' | ||
Line 119: | Line 119: | ||
**[http://partsregistry.org/Part:BBa_K914016 K914016] coding sequence of Colicin E2 | **[http://partsregistry.org/Part:BBa_K914016 K914016] coding sequence of Colicin E2 | ||
</div> | </div> | ||
+ | |||
+ | </td> | ||
+ | </tr> | ||
+ | </table> | ||
+ | |||
<table id="tableboxed"> | <table id="tableboxed"> |
Revision as of 23:16, 26 October 2012
Semantic containment
Aims
System
Achievements :
Both part were well characterized and works well. For the second parts, we show that as expected, one mutation is quite leaky, although it works qualitatively, but one mutation is not enough if we want to release such parts in nature. Other reasons emphasize this observation, notably the weakness of being at one mutation to recover the protein functionality.
Achievements :
|
Suicide system
Aims : Implement a kill-switch that features population-level suicide and complete genome degradation. System : A synthetic toxin-anti-toxin system based on the wild type Colicin E2 operon. Achievements : We showed that Colicin E2 cells induce cell death in sensitive populations, and that these sensitive populations can be protected by providing them with our engineered immunity protein.
Part K914001 is well characterized and provides immunity to sensitive cells against the Colicin E2 activity protein, but is leaky. Part K914002 is promoterless and allows users to easily plug in the appropriate promoter for their desired purpose.
|
Restriction Enzyme System
Aim: To design a plasmid self-digestion system. Experimental System: We are testing different combinations of promoters and restriction enzymes. We have to characterize both the promoters (by measuring the expression of RFP) and the restriction enzymes (by measuring killed cells). Achievements :
|
Delay System
Aim : A programmed delay will allow the cell to perform its intended function before our DNA-degrading suicide machinery is expressed. Experimental system: We used two different approaches to create this delay. The first one is based on the gradual dilution of a regulatory transcription factor. The second one makes use of a stationary-phase specific promoter. Both systems eventually result in the expression of the restriction enzyme I-SceI. In the final design, I-SceI cleaves the antitoxin gene, ultimately dooming the cell. Each step in this causal sequence contributes to the overall delay in the system.
Achievements :
|
MAGE
Aims : Removal of four FseI restriction sites from E. coli MG1655 genome. Experimental System: Using multiplex automated genome engineering (MAGE) - a technique capable of editing the genome by making small changes in existing genomic sequences. Achievements: Proof of concept by introducing a stop codon in the middle of the lacZ gene |
Synthetic Import Domain
Creation of a novel protein import mechanism in bacteria.
Exploit the natural Colicin import domain fused to any protein at will, dubbed here: "Synthetic Import Domain". Achievements:
|
Encapsulation
Aim: Harness bacteria-containing gel beads to assure cell containment and complement activity of genetic safety systems. Experimental system: Bacterial cells are encapsulated in alginate beads. We used a cell containment assay based on plating to assess the release of cells from alginate beads. In addition, we aimed at improving the entrapment of cells through stabilization by polyethyleneimine and covalent cross-linkage by glutaraldehyde. Achievements:
|
Human Practice
Aims
Human concerns arose organically during the construction of the bWARE containment system, and human practices were intrinsic to every stage of our project. In designing and building our best genetic containment system, we often encountered limits on the ability of science alone to measure our performance. When is a biosafety system safe enough? The answer to this question is partially scientific, to the extent that horizontal gene transfer events can be observed and modeled. But the answer is also social, because ultimately the public will decide if a biosafety system works well enough to use. The only way for us to know if bWARE is a success is in conversation with experts and the community. We propose and implement new ways for iGEM to organize and present biosafety information, both for scientists and the public. We believe our reforms to the BioBrick registry will help synthetic biologists to find the best biosafety tools for their application. We also imagine the beginnings of a quantitative, context-specific biosafety database serving citizen scientists. Practical safety data will feed an informed public forum.
You can find the full list of conclusions here Main Proposals
You can find the full list of proposals here |